Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
Completed · Phase 2 · NCT05305989
Conditions: Chronic Graft-versus-host-disease
At a glance
- Research payments reported, 2025
- $5,000
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 23
About the trial
- Sponsor
- Kadmon, a Sanofi Company
- Tested
- Belumosudil 200 mg QD (drug), Belumosudil 200 mg BID (drug), Belumosudil 400 mg QD (drug)
- Dates
- Started 2022-02-23; completion 2024-06-06
- Results posted
- Yes
Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213
From ClinicalTrials.gov, last updated 2025-05-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi-aventis U.S. LLC reported $5,000 in research payments for this study in 2025 (4 payments).
Products named: Rezurock
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $5,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.